BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Business

  Aralez Announces Third Quarter 2017 Financial Results And Achieves Profitability on an Adjusted EBITDA Basis for the First Time in the Third Quarter

  Based on the Company’s preliminary 2018 outlook, the Company is expected to transition into a growth phase of its corporate evolution and pivot into a profitable (on an Adjusted EBITDA basis) and growth Company.

  November 9, 2017

   · 

  38 min read
• Business

  BioLineRx to Report Third Quarter 2017 Results on November 21, 2017

  Management to hold a conference call at 10:00 a.m. ET.

  November 9, 2017

   · 

  3 min read
• 

  Business

  Ionis Licenses Novel Antisense Drug for the Treatment of Centronuclear Myopathy to Dynacure

  Ionis earns $5 million license fee from Dynacure.

  November 9, 2017

   · 

  5 min read
• Business

  Galmed Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update

  A conference call and webcast is scheduled for oday at 8:30 a.m. ET / 5:30 a.m. PT.

  November 9, 2017

   · 

  18 min read
• Business

  Impax Reports Third Quarter 2017 Results

  Total revenues in the third quarter 2017 were $206.4 million, a decrease of 9.4%, compared to $227.9 million in the prior year period as a decrease in sales of generic products was partially offset by an increase in sales of specialty products.

  November 9, 2017

   · 

  72 min read
• Drug Development

  AcelRx Pharmaceuticals Reports Publication of Manuscript Evaluating Sufentanil Sublingual Tablets for Moderate-to-Severe Acute Pain in the Emergency Department

  This manuscript reports on the results of an open-label, multicenter feasibility study which included opiate-naïve patients who presented to the ED with moderate-to-severe pain due to trauma or injury.

  November 9, 2017

   · 

  5 min read
• Business

  Titan Pharmaceuticals Reports Third Quarter 2017 Financial Results

  Titan reported approximately $40,000 in license revenue from royalties earned on net sales of Probuphine by Braeburn, compared with approximately $26,000 in the same period a year ago.

  November 9, 2017

   · 

  15 min read
• Business

  Concert Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Company Update

  Cash, cash equivalents and investments as of September 30, 2017, totaled $207.1 million as compared to $103.4 million as of June 30, 2017.

  November 9, 2017

   · 

  8 min read
• Business

  ReadCoor Collaborates With The Joint Pathology Center

  ReadCoor, a company reinventing omics and pathology with its panomic spatial sequencing platform, today announced a collaboration with The Joint Pathology Center (JPC), the premier pathology reference center for the United States government.

  November 9, 2017

   · 

  2 min read
• Business

  ArQule Reports Third Quarter 2017 Financial Results

  For the quarter ended September 30, 2017, the Company reported a net loss of $6,666,000 or $0.09 per share, compared with a net loss of $5,817,000 or $0.08 per share, for the third quarter of 2016.

  November 9, 2017

   · 

  12 min read